Superior Tumor Detection for (68)Ga-FAPI-46 Versus (18)F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma

Management of cholangiocarcinoma is among other factors critically determined by accurate staging. Here, we aimed to assess the accuracy of PET/CT with the novel cancer fibroblast–directed (68)Ga-fibroblast activation protein (FAP) inhibitor (FAPI)-46 tracer for cholangiocarcinoma staging and manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Pabst, Kim M., Trajkovic-Arsic, Marija, Cheung, Phyllis F.Y., Ballke, Simone, Steiger, Katja, Bartel, Timo, Schaarschmidt, Benedikt M., Milosevic, Aleksandar, Seifert, Robert, Nader, Michael, Kessler, Lukas, Siveke, Jens T., Lueckerath, Katharina, Kasper, Stefan, Herrmann, Ken, Hirmas, Nader, Schmidt, Hartmut H., Hamacher, Rainer, Fendler, Wolfgang P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315700/
https://www.ncbi.nlm.nih.gov/pubmed/37024301
http://dx.doi.org/10.2967/jnumed.122.265215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315700/
https://www.ncbi.nlm.nih.gov/pubmed/37024301
http://dx.doi.org/10.2967/jnumed.122.265215

Ejemplares similares